Literature DB >> 2354443

Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.

J A Houghton1, L G Williams, P J Cheshire, I W Wainer, P Jadaud, P J Houghton.   

Abstract

Using preclinical models of human colon adenocarcinomas in immune-deprived mice, the influence of dose of [6RS]leucovorin ([6RS]LV, 20 to 1000 mg/m2) administered by 24-h i.v. infusion was determined on the following parameters: (a) plasma concentrations of the active [6S] and inactive [6R] isomers of [6RS]LV and the biologically active diastereoisomer of 5-methyltetrahydrolate (5-CH3-H4PteGlu); (b) expansion of intratumor pools of 5,10-methylenetetrahydrofolates (CH2-H4PteGlun) and tetrahydrofolates (H4PteGlun), that may influence the binding of 5-fluorodeoxyuridylate to thymidylate synthase; (c) the distribution of polyglutamate forms of CH2-H4PteGlun and H4PteGlun; and (d) (5-fluorouracil (FUra)-mediated thymidylate synthase inhibition in Hx-ELC2, HxGC3, HxVRC5, and HxHC1 tumors. Folypolyglutamate synthetase activities were also determined in each line. Linear increases in plasma concentrations of [6R]LV, [6S]LV, and 5-CH3-H4-PteGlu were determined over the complete range of [6RS]LV doses examined. However, in neoplastic tissues three patterns of biochemical modulation by [6RS]LV were evident. (a) In HxELC2 and HxVRC5 tumors, pools of CH2-H4PteGlun and H4PteGlun were elevated in proportion to the dose of [6RS]LV between dose levels of 50 and 200 mg/m2. Subsequent expansion of these pools continued that was disproportionate to the dose of [6RS]LV until no further increase was observed beyond 800 mg/m2 [6RS]LV, at which point pools were maximally expanded by 4- to 4.5-fold. The extent of retardation of recovery of thymidylate synthase activity increased as the dose of [6RS]LV was increased in both tumors, when FUra (15 or 50 mg/kg), was administered by i.v. bolus injection 3 h into the 24-h infusion of [6RS]LV. This was related to the increase in predominance of CH2-H4PteGlu2-5 with increasing dose of [6RS]LV. (b) For HxHC1 tumors, little expansion of CH2-H4PteGlun and H4PteGlun pools (maximum, 137% of control) was detected at the highest dose levels of [6RS]LV, and no significant modulation of FUra-inhibited thymidylate synthase activity was detected, even at 1000 mg/m2 [6RS] LV. CH2-H4PteGlu5 remained similar or decreased as the dose of [6RS] LV was increased. (c) For line HxGC3, pools of CH2-H4PteGlun and H4PteGlun increased gradually from 169% of control at 20 mg/m2 [6RS] LV to 233% of control at 1000 mg/m2 [6RS]LV, and were intermediate between the expansion observed in HxHC1 in comparison to HxELC2 and HxVRC5 tumors. CH2-H4PteGlu3-5 were elevated at low dose levels of [6RS]LV.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354443

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy.

Authors:  Elisabeth Odin; Arvid Sondén; Bengt Gustavsson; Göran Carlsson; Yvonne Wettergren
Journal:  Mol Med       Date:  2015-07-17       Impact factor: 6.354

2.  Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.

Authors:  David Machover; Emma Goldschmidt; Wathek Almohamad; Vincent Castagné; Julien Dairou; Christophe Desterke; Léa Gomez; Yann Gaston-Mathé; Claude Boucheix
Journal:  Sci Rep       Date:  2022-05-31       Impact factor: 4.996

3.  Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; A Rogatko; E M Newman; C McAleer; J Brennan; F P LaCreta; G R Hudes; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; A E Sieder; G Locker; M F Gnant; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

5.  The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.

Authors:  S Kase; T Kubota; M Watanabe; T Takahara; T Takeuchi; H Yamaguchi; T Furukawa; T Teramoto; S Kodaira; K Ishibiki
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

6.  Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.

Authors:  J A Houghton; L G Williams; S K Loftin; P J Cheshire; C L Morton; P J Houghton; A Dayan; J Jolivet
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Intracellular metabolism of 5-methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line.

Authors:  D M Voeller; C J Allegra
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.

Authors:  David Machover; Wathek Almohamad; Vincent Castagné; Christophe Desterke; Léa Gomez; Yann Gaston-Mathé; Claude Boucheix; Emma Goldschmidt
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.